Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome (RAZANT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03274973
Recruitment Status :
(Insufficient, delayed recruitment of participants)
Assessment of long-term effectiveness of ZOMACTON in treatment of Growth Hormone Deficiency or growth retardation due to Ullrich-Turner Syndrome and assessment of compliance and adherence, optionally with the aid of an electronic app or patient diary.
A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome
Actual Study Start Date :
May 14, 2018
Actual Primary Completion Date :
October 31, 2018
Actual Study Completion Date :
October 31, 2018
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Pediatric outpatient clinic
Pediatric patients (< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome
Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study.
Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data.
Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period
Product Manufactured in and Exported from the U.S.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Disorders of Sex Development
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Sex Chromosome Disorders
Genetic Diseases, Inborn
Endocrine System Diseases